Inogen (INGN)
(Delayed Data from NSDQ)
$8.69 USD
-0.04 (-0.46%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $8.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.69 USD
-0.04 (-0.46%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $8.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
by Zacks Equity Research
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
Looking for Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Inogen (INGN) Up 14.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Inogen (INGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Can Inogen (INGN) Stock Continue to Grow Earnings?
by Zacks Equity Research
Inogen (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
by Zacks Equity Research
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Align Technology International Growth Solid, Rivalry Rife
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
by Zacks Equity Research
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
DaVita Healthcare Partners' New Facility Now in Los Angeles
by Zacks Equity Research
DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.
Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure
by Zacks Equity Research
Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.
Hologic Launches Fluent Fluid Management System, Widens Suite
by Zacks Equity Research
Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INGN) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Wright Medical Strong Overseas, Back Order Issues Persist
by Zacks Equity Research
Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.